Anti-obesity drugs and neural circuits of feeding

被引:80
|
作者
Adan, Roger A. H. [1 ]
Vanderschuren, Louk J. M. J. [1 ]
la Fleur, Susanne E. [1 ]
机构
[1] UMC Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurosci & Pharmacol, NL-3584 CG Utrecht, Netherlands
关键词
D O I
10.1016/j.tips.2008.01.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most of the drugs that have entered the market for treating obesity were originally developed to treat psychiatric diseases. During the past decade, understanding of the neural circuits that underlie food intake has increased considerably. Different aspects of ingestive behavior such as meal termination, meal initiation and overconsumption of highly rewarding and palatable foods are modulated by different neuroanatomical structures. Integration of the action of many signaling molecules (e.g. hormones, neurotransmitters and neuropeptides) in these structures results in a response that, ultimately, modulates food intake. Thus, the type of drug required by an obese patient might depend on the individual cause of obesity. In this article, we summarize the neural circuits that regulate food intake and we provide a framework for understanding how obesity drugs function. Several potential drug targets are expressed in different neural circuits, implying that current and future obesity drugs act on partially overlapping systems that control food intake.
引用
收藏
页码:208 / 217
页数:10
相关论文
共 50 条
  • [31] Serotonergic targets for novel anti-obesity drugs
    Simansky, K. J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 127 - 127
  • [32] Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
    Gitanjali Srivastava
    Caroline Apovian
    Current Obesity Reports, 2018, 7 : 147 - 161
  • [33] Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
    Srivastava, Gitanjali
    Apovian, Caroline
    CURRENT OBESITY REPORTS, 2018, 7 (02): : 147 - 161
  • [34] The obesity pipeline: current strategies in the development of anti-obesity drugs
    Dunstan Cooke
    Steve Bloom
    Nature Reviews Drug Discovery, 2006, 5 : 919 - 931
  • [35] The obesity pipeline: current strategies in the development of anti-obesity drugs
    Cooke, Dunstan
    Bloom, Steve
    NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (11) : 919 - 931
  • [36] Cardiovascular Effects of Current and Future Anti-Obesity Drugs
    Comerma-Steffensen, Simon
    Grann, Martin
    Andersen, Charlotte U.
    Rungby, Jorgen
    Simonsen, Ulf
    CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (03) : 493 - 504
  • [37] A risk-benefit assessment of anti-obesity drugs
    Kolanowski, J
    DRUG SAFETY, 1999, 20 (02) : 119 - 131
  • [38] Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
    Son, Jang Won
    Kim, Sungrae
    DIABETES & METABOLISM JOURNAL, 2020, 44 (06) : 802 - 818
  • [39] Regulation of food intake and the development of anti-obesity drugs
    Chen, Yue
    DRUG DISCOVERIES AND THERAPEUTICS, 2016, 10 (02): : 62 - 73
  • [40] EFFECT OF ANTI-OBESITY DRUGS ON LIPASE ACTIVITY INVITRO
    HOLMES, JH
    SAPEIKA, N
    ZWARENSTEIN, H
    RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, 1975, 10 (04): : 739 - 742